HC Wainwright & Co. Downgrades Landos Biopharma to Neutral, Lowers Price Target to $20.42
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju downgraded Landos Biopharma (NASDAQ:LABP) from Buy to Neutral and reduced the price target from $50 to $20.42.
April 01, 2024 | 11:12 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Landos Biopharma was downgraded by HC Wainwright & Co. from Buy to Neutral, with a significant reduction in price target from $50 to $20.42.
The downgrade from Buy to Neutral by a reputable analyst firm, along with a substantial decrease in the price target, is likely to negatively impact investor sentiment towards Landos Biopharma in the short term. This could lead to a decrease in stock price as investors adjust their expectations based on the new analyst outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100